472 related articles for article (PubMed ID: 26531137)
41. Fetal porcine thymus engraftment, survival and CD4 reconstitution in alphaGal-KO mice is impaired in the presence of high levels of antibodies against alphaGal.
Rodriguez-Barbosa JI; Zhao Y; Houser S; Zhao G; Sykes M
Xenotransplantation; 2003 Jan; 10(1):24-40. PubMed ID: 12535223
[TBL] [Abstract][Full Text] [Related]
42. Production of alpha 1,3-galactosyltransferase-deficient pigs.
Phelps CJ; Koike C; Vaught TD; Boone J; Wells KD; Chen SH; Ball S; Specht SM; Polejaeva IA; Monahan JA; Jobst PM; Sharma SB; Lamborn AE; Garst AS; Moore M; Demetris AJ; Rudert WA; Bottino R; Bertera S; Trucco M; Starzl TE; Dai Y; Ayares DL
Science; 2003 Jan; 299(5605):411-4. PubMed ID: 12493821
[TBL] [Abstract][Full Text] [Related]
43. The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation.
Galili U
Biochimie; 2001 Jul; 83(7):557-63. PubMed ID: 11522383
[TBL] [Abstract][Full Text] [Related]
44. Effects of interfering RNA of α-1,3-galactosyltransferase and nuclear factor-kappa B on cardiac xenotransplantation.
Cao JS; Qi F; Lu CY; Gu YC; Zhu LW
Transpl Immunol; 2014 Sep; 31(3):173-82. PubMed ID: 25128705
[TBL] [Abstract][Full Text] [Related]
45. Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope.
Sadoulet MO; Franceschi C; Aubert M; Silvy F; Bernard JP; Lombardo D; Mas E
Glycobiology; 2007 Jun; 17(6):620-30. PubMed ID: 17374617
[TBL] [Abstract][Full Text] [Related]
46. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
Galili U; Wigglesworth K; Abdel-Motal UM
J Immunol; 2007 Apr; 178(7):4676-87. PubMed ID: 17372027
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U
J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270
[TBL] [Abstract][Full Text] [Related]
48. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.
LaTemple DC; Galili U
Xenotransplantation; 1998 Aug; 5(3):191-6. PubMed ID: 9741457
[TBL] [Abstract][Full Text] [Related]
49. Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA.
Deriy L; Chen ZC; Gao GP; Galili U
Glycobiology; 2002 Feb; 12(2):135-44. PubMed ID: 11886847
[TBL] [Abstract][Full Text] [Related]
50. Immune responses to alpha1,3 galactosyltransferase knockout pigs.
Puga Yung G; Schneider MK; Seebach JD
Curr Opin Organ Transplant; 2009 Apr; 14(2):154-60. PubMed ID: 19300259
[TBL] [Abstract][Full Text] [Related]
51. L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies.
Chen W; Gu L; Zhang W; Motari E; Cai L; Styslinger TJ; Wang PG
ACS Chem Biol; 2011 Feb; 6(2):185-91. PubMed ID: 21043478
[TBL] [Abstract][Full Text] [Related]
52. Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Galalpha1-3Galbeta1-4betaGlc-X immunoaffinity column.
Xu Y; Lorf T; Sablinski T; Gianello P; Bailin M; Monroy R; Kozlowski T; Awwad M; Cooper DK; Sachs DH
Transplantation; 1998 Jan; 65(2):172-9. PubMed ID: 9458010
[TBL] [Abstract][Full Text] [Related]
53. Acceleration of wound healing by α-gal nanoparticles interacting with the natural anti-Gal antibody.
Galili U
J Immunol Res; 2015; 2015():589648. PubMed ID: 25922849
[TBL] [Abstract][Full Text] [Related]
54. Changes in cell surface glycosylation in alpha1,3-galactosyltransferase knockout and alpha1,2-fucosyltransferase transgenic mice.
Shinkel TA; Chen CG; Salvaris E; Henion TR; Barlow H; Galili U; Pearse MJ; d'Apice AJ
Transplantation; 1997 Jul; 64(2):197-204. PubMed ID: 9256173
[TBL] [Abstract][Full Text] [Related]
55. Glycolipid studies in small intestine and pancreas of alpha1,3-galactosyltransferase knockout miniature swine: alpha1,3GALT-KO animals lack alphaGAL antigens and contain novel blood group H compounds.
Diswall M; Angström J; Schuurman HJ; Dor FJ; Rydberg L; Breimer ME
Transplant Proc; 2008 Mar; 40(2):543-6. PubMed ID: 18374124
[TBL] [Abstract][Full Text] [Related]
56. The influence of natural antibody specificity on antigen immunogenicity.
Benatuil L; Kaye J; Rich RF; Fishman JA; Green WR; Iacomini J
Eur J Immunol; 2005 Sep; 35(9):2638-47. PubMed ID: 16082726
[TBL] [Abstract][Full Text] [Related]
57. Xenotransplantation: the importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection.
Joziasse DH; Oriol R
Biochim Biophys Acta; 1999 Oct; 1455(2-3):403-18. PubMed ID: 10571028
[TBL] [Abstract][Full Text] [Related]
58. Anti-Gal antibodies in humans and 1, 3alpha-galactosyltransferase knock-out mice.
Chiang TR; Fanget L; Gregory R; Tang Y; Ardiet DL; Gao L; Meschter C; Kozikowski AP; Buelow R; Vuist WM
Transplantation; 2000 Jun; 69(12):2593-600. PubMed ID: 10910282
[TBL] [Abstract][Full Text] [Related]
59. Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer.
Katopodis AG; Warner RG; Duthaler RO; Streiff MB; Bruelisauer A; Kretz O; Dorobek B; Persohn E; Andres H; Schweitzer A; Thoma G; Kinzy W; Quesniaux VF; Cozzi E; Davies HF; Mañez R; White D
J Clin Invest; 2002 Dec; 110(12):1869-77. PubMed ID: 12488437
[TBL] [Abstract][Full Text] [Related]
60. Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice.
Posekany KJ; Pittman HK; Swanson MS; Haisch CE; Verbanac KM
Anticancer Res; 2004; 24(2B):605-12. PubMed ID: 15161001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
